The Robert's Rebellion prequel story is getting the Royal Shakespeare Company treatment, and will have "all the epic qualities audiences expect." By James Hibberd Writer-at-Large The world of George R ...

PROVIDENCE — As he runs for reelection, Democratic Governor Daniel J. McKee is touting proposals to slash energy costs — part of an “affordability” agenda popular among Democratic officials from New ...

While the artificial intelligence industry touts that AI will replace entry-level jobs, not every company is scaling back hiring these positions. In IBM’s case, it’s going all in. Hardware giant IBM ...

Update: Made a couple of corrections and added additional information. Carolyn Krause is exploring what’s happening in Oak Ridge. She has read that new companies are investing in building facilities ...

Add Yahoo as a preferred source to see more of our stories on Google. Dept. Of War Confirms Plans To Scale ‘Directed Energy Weapons’ Image by CS StockShutterstock The Department of War has confirmed ...

Experimental molecule may be a potent weapon against Alzheimer’s By Malcolm Azania January 07, 2026 The NU-9 molecule may one day delay or even prevent the destruction of neurons that begins decades ...

Westeros might be getting even more crowded. George R.R. Martin says several Game of Thrones projects are still quietly moving through development at HBO — and not all of them are set in the past. HBO ...

Semitransparent solar cells with natural looking color and strong heat blocking offer a realistic way for windows to generate electricity and cut energy use in large buildings. (Nanowerk Spotlight) ...

Virgin Media O2 is taking further steps toward its net zero carbon emissions goal through a new agreement with The Renewables Infrastructure Group (TRIG). As part of the 10-year deal TRIG will provide ...

Kerry Breen is a news editor at CBSNews.com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital. She covers current events, ...

In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free ...

To join the CNBC Technology Executive Council, go to cnbccouncils.com/tec Postings for entry-level jobs in the U.S. overall have declined about 35% since January 2023 ...